Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands

Fernie Penning-van Beest; Jeroen Koerselman
December 2007
Pharmacy World & Science;Dec2007, Vol. 29 Issue 6, p671
Academic Journal
Abstract Objective  Coumarin anticoagulants are prone to potentially life-threatening drug-drug interactions due to a combination of unfavorable properties. However, real life data on the actual occurrence are scarce. The aim of this study was to quantify and qualify potential drug interactions with coumarin anticoagulants in daily practice. Methods  A cohort study including all users of phenprocoumon or acenocoumarol during the period 1991–2003 in the PHARMO Record Linkage System. All 24 individual drugs and 11 drug groups interacting with coumarins according to central database used in the Dutch pharmacies were considered. Main outcome measure  Frequency and type of potential drug interactions during anticoagulant therapy with coumarins. Results  48,627 out of 76,455 mainly acenocoumarol-users (64%) were dispensed at least one potentially interacting drug (PID) during anticoagulant therapy. About 35% of these cases were dispensed a (very) strongly interacting drug, whereas 3% were dispensed a contraindicated drug. Antibacterial drugs and NSAIDs (39% and 37% of all users, respectively) were the most frequently dispensed PIDs. Conclusion  Potential drug interactions with coumarins frequently occur in daily practice, confronting two-thirds of patients with an increased risk of bleeding. To a large part, this is attributable to commonly prescribed medication like antibacterial drugs and NSAIDs. This situation substantiates the need for proper monitoring or new anticoagulants with less drug–drug interactions.


Related Articles

  • Drug interaction: Omeprazole and Phenprocoumon. Enderle, Christa; Müller, Willi; Grass, Ulrich // BMC Gastroenterology;2001, Vol. 1, p2 

    Background: Oral anticoagulants like the coumarin derivatives are characterised by a particularly narrow therapeutic range. Any interfering co-medication can pose a challenge to establishing a stable anticoagulant dosage regimen and thus present a serious risk for the patient. Here we describe...

  • Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Schalekamp, Tom; van Geest-Daalderop, Johanna H. H.; Kramer, Mark K. H.; van Holten-Verzantvoort, Angelique T. M.; de Boer, Anthonius // European Journal of Clinical Pharmacology;Apr2007, Vol. 63 Issue 4, p335 

    The objective of our study was to examine the management of the interaction between acenocoumarol or phenprocoumon and several antibiotics by anticoagulation clinics and to compare the consequences of this interaction on users of co-trimoxazole with those for users of other antibiotics. A...

  • Drug interaction between capecitabine and warfarin.  // WHO Drug Information;2006, Vol. 20 Issue 1, p9 

    The article presents information related to the coadministration of drugs capecitabine and warfarin for the treatment of breast cancer. Capecitabine is a cytostatic agent indicated for metastatic breast cancer when used as an adjunct to docetaxel. A patient can be predisposed to an increased...

  • Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Penning-van Beest, Fernie; Erkens, Joëlle; Petersen, Karl-Uwe; Koelz, Hans; Herings, Ron // European Journal of Clinical Pharmacology;Jul2005, Vol. 61 Issue 5/6, p439 

    Objective: To study the main comedications associated with major bleeding during anticoagulant therapy with coumarins in a non-selected population under everyday circumstances. Methods: The study population for this retrospective cohort study included all new users of phenprocoumon or...

  • Balancing your anticoagulant.  // Mayo Clinic Health Letter;Jun1998, Vol. 16 Issue 6, p2 

    Looks at concerns of drug interaction with anticoagulants, which include heparin and warfarin. Importance of consistency in medication and foods to maintain the proper levels of anticoagulant in the blood; Information on drugs which cause problems with anticoagulants.

  • New blood-thinning drugs hold promise, but pose risk.  // Journal of Business (10756124);6/17/2010, Vol. 25 Issue 13, pB8 

    The article reports that three new oral blood-thinning drugs that are nearing approval by the U.S. Food and Drug Administration are more convenient that the standard drug Coumadin but could cause dangerous interactions when taken alongside widely used prescription drugs and over-the-counter...

  • Aspirin/clopidogrel/warfarin.  // Reactions Weekly;7/30/2011, Issue 1362, p9 

    The article describes the case of a 73-year-old woman who developed intramuscular haematomas resulting to femoral neuropathy while undergoing anticoagulant therapy with aspirin, clopidogrel and warfarin.

  • Apixaban.  // Reactions Weekly;Apr2015, Vol. 1546 Issue 1, p35 

    The article presents case report of a patient who experienced minor haemorrhage during treatment with apixaban.

  • WHAT TO WATCH FOR WITH coumarin. Kirschenbaum, Harold L.; Rosenberg, Jack M. // RN;Oct82, Vol. 45 Issue 10, p54 

    Provides a guide on prescribing an oral anticoagulant called coumarin. Description of the drug; Derivatives; Interactions and reactions with other drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics